Compare Ascendis Pharma A/S (ASND) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Anheuser-Busch Inbev SA — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Anheuser-Busch Inbev SA trades at $79.59 (market cap $159.01B). The key difference: Anheuser-Busch Inbev SA is far larger — about 9.5× Ascendis Pharma A/S's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BUD | |
|---|---|---|
Market Cap | $16.67B | $159.01B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $86.48 |
52-Week Low | $189.74 | $57.93 |
Enterprise Value | $17.04B | $223.42B |
Dividend Yield | — | 1.67% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
